Perindopril in patients after myocardial infarction with diabetes – experience of the Cracow center Case report
Article Sidebar
Main Article Content
Abstract
Patients after myocardial infarction are more vulnerable to have another coronary incident and clinical status of the patients and their treatment may be complicated by concomitant diabetes. We present below two cases of the patients hospitalized in department of cardiology in Cracow, in whom angiotensin converting enzyme inhibitors have not been used before e.g. due to renal insufficiency and concern about exacerbation of renal failure. This group of drugs has proven efficiency in patients after myocardial infarction and concomitant diabetes so it is necessary to consider including angiotensin converting enzyme inhibitor in patient’s pharmacotherapy.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Indeks leków Medycyny Praktycznej 2007. Wydawnictwo Medycyna Praktyczna, Kraków 2007: 528.
3. Kumar M., Mohan L., Dikshit H.: Study of Changes in Renal Function by Perindopril and Telmisartan during Treatment of Systemic Hypertension. J. Clin. Diagn. Res. 2014; 8(4): HC07-HC09.
4. Perkovic V., Ninomiya T., Arima H. et al.: Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study. J. Am. Soc. Nephrol. 2007; 10: 2766-2772.
5. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
6. Daly C., Fox K.M., Remme W.J. et al.: The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur. Heart. J. 2005; 26: 1369-1378.
7. de Luca N., Mallion J.M., O’Rourke M.F. et al.: Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am. J. Hypertens. 2004; 17(8): 660-667.
8. Asmar R., Topouchian J., Pannier B. et al.: Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J. Hypertens. 2001; 19(4): 813-818.
9. Mancia G., Grassi G.: Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. J. Hypertens. Suppl. 2009; 27(1): S19-23.